Ondansetron

Generic Name
Ondansetron
Brand Names
Zofran, Zuplenz
Drug Type
Small Molecule
Chemical Formula
C18H19N3O
CAS Number
99614-02-5
Unique Ingredient Identifier
4AF302ESOS
Background

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis.

The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.

Indication

In the adult patient population:

i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and

- the prevention and treatment of postoperative nausea and vomiting

ii) intravenously administered ondansetron injection formulations are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and

- the prevention and treatment of postoperative nausea and vomiting

In the pediatric (4-18 years of age) patient population:

i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting,

ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger,

iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and

iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting

In the geriatric (>65 years of age) patient population:

i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and

ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population

Associated Conditions
Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
Associated Therapies
-

Ultrasound-guided Blocks for Ambulatory Knee Arthroscopy

First Posted Date
2013-04-23
Last Posted Date
2013-11-06
Lead Sponsor
Jens Borglum Neimann
Target Recruit Count
60
Registration Number
NCT01837394
Locations
🇩🇰

Department of Anesthesiology, Bispebjerg Hospital, Copenhagen, Denmark

Ondansetron for Pediatric Mild Traumatic Brain Injury

First Posted Date
2013-03-20
Last Posted Date
2015-09-29
Lead Sponsor
St. Justine's Hospital
Target Recruit Count
16
Registration Number
NCT01815125
Locations
🇨🇦

CHU Sainte-Justine, Montreal, Quebec, Canada

How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-02-28
Last Posted Date
2015-06-01
Lead Sponsor
Stanford University
Target Recruit Count
100
Registration Number
NCT01801475
Locations
🇺🇸

Lucile Packard Children's Hospital & Stanford Hospital, Palo Alto, California, United States

Ondansetron and the QT Interval In Adult Emergency Department Patients

Completed
Conditions
Interventions
First Posted Date
2013-01-03
Last Posted Date
2014-06-26
Lead Sponsor
C.R.Darnall Army Medical Center
Target Recruit Count
28
Registration Number
NCT01759420
Locations
🇺🇸

Carl R Darnall Army Medical Center, Fort Hood, Texas, United States

🇺🇸

Madigan Army Medical Center, Tacoma, Washington, United States

Analgesic Effect of IV Acetaminophen in Tonsillectomies

First Posted Date
2012-09-25
Last Posted Date
2017-04-06
Lead Sponsor
Nationwide Children's Hospital
Target Recruit Count
250
Registration Number
NCT01691690
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.

First Posted Date
2012-09-05
Last Posted Date
2016-10-27
Lead Sponsor
University Hospital, Lille
Target Recruit Count
66
Registration Number
NCT01679093
Locations
🇫🇷

Hôpital Claude Huriez, CHRU, Lille, France

Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension

First Posted Date
2012-08-20
Last Posted Date
2012-08-20
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
100
Registration Number
NCT01669213
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath